From The Corner Lab - Blog Posts

Indian Government Moves to Ban Medicines From Being Sold Under Branded Names

Posted by Jim Menoutis on Fri, Oct 19, 2012 @ 04:39 PM

The Drug controller general  of India has moved to  prohibit medicines from being sold under brand names. As a result, earlier this week, states were ordered to stop issuing licenses for the manufacture or sale of drugs under brand names This move is already raising objections from domestic drug makers. The effort is designed to accelerate the sale of lower-cost generics in India.

Read More

Topics: Generics, Indian Pharmaceuticals, Indian Generics, India Trademarks, Non-branded drugs

Merck To Relocate Its Headquarters

Posted by Jim Menoutis on Wed, Oct 10, 2012 @ 01:18 PM

Since 1992, Merck has called  Whitehouse Station, NJ home to its corporate headquarters. Now followings its merger with Schering Plough in 2009, it has decided to close and shutter the facility, relocating its headquarters and some  2,00 employees and contractors to new digs scattered around New Jersey. And the company is billing the move as a sign of its increasing corporate.

Read More

Topics: USP, Life science research, Generics, Generic Version, Roche, Merck, Merck R&D, Merck Whitehouse Station, Merck to Move, Sanofi

Teva Pulls Generic Version of Wellbutrin XL From U.S. Market

Posted by Jim Menoutis on Fri, Oct 05, 2012 @ 02:31 PM

Teva Pharmaceuticals is pulling its generic version of Wellbutrin XL. After extended testing, the FDA has determined that Teva's generic isn't equivalent to the branded drug. And now, the FDA is requiring other generics companies to test whether their own versions of Wellbutrin XL are acceptable (read Bloomberg story).

Read More

Topics: FDA, Generics, Generic Version, Teva, Wellburtin XL, Budeprion XL